Eling Pharmaceutical announced that its wholly-owned subsidiary, Beijing Eling's exclusive product, Astragalus Anti-Nasal Tablets, passed medical insurance negotiations and was included in the “National Health Insurance Catalogue” for the first time. This medicine is class 1.1 of traditional Chinese medicine. It is used to treat persistent allergic rhinitis. The medical insurance payment standard is 1.78 yuan/tablet, and the agreement is valid until December 31, 2027. Previously, the drug had obtained registration approval from the State Drug Administration and the Macau Proprietary Chinese Medicine Registration Certificate. In addition to astragalus nasal tablets, the company also has 11 exclusive varieties in this catalog. The inclusion of 12 products in the catalogue this time has had a positive impact on the company's long-term operations, but the impact on performance cannot yet be estimated, and it is expected that there will be no significant impact in the short term.

Eling Pharmaceutical announced that its wholly-owned subsidiary, Beijing Eling's exclusive product, Astragalus Anti-Nasal Tablets, passed medical insurance negotiations and was included in the “National Health Insurance Catalogue” for the first time. This medicine is class 1.1 of traditional Chinese medicine. It is used to treat persistent allergic rhinitis. The medical insurance payment standard is 1.78 yuan/tablet, and the agreement is valid until December 31, 2027. Previously, the drug had obtained registration approval from the State Drug Administration and the Macau Proprietary Chinese Medicine Registration Certificate. In addition to astragalus nasal tablets, the company also has 11 exclusive varieties in this catalog. The inclusion of 12 products in the catalogue this time has had a positive impact on the company's long-term operations, but the impact on performance cannot yet be estimated, and it is expected that there will be no significant impact in the short term.